T. Rowe Price Investment Management, Inc. Arcellx, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $164 Billion
- Q3 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Arcellx, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 6,352,356 shares of ACLX stock, worth $572 Million. This represents 0.32% of its overall portfolio holdings.
Number of Shares
6,352,356
Previous 1,943,726
226.81%
Holding current value
$572 Million
Previous $128 Million
307.46%
% of portfolio
0.32%
Previous 0.08%
Shares
9 transactions
Others Institutions Holding ACLX
# of Institutions
226Shares Held
51.4MCall Options Held
85.4KPut Options Held
113K-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$418 Million12.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.91MShares$352 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$316 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.05MShares$274 Million15.63% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$273 Million4.28% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.94B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...